Effects of dorsal periaqueductal gray CRF1- and CRF2-receptor stimulation in animal models of panic

Psychoneuroendocrinology

Volumn 49, Issue 1, 2014, Pages 321-330

  de Oliveira Sergio, Thatiane ^a   Spiacci, Ailton ^a   Zangrossi, Hélio ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anxiety; CRF; Dorsal periaqueductal gray; Elevated T maze; Escape; Inhibitory avoidance; Panic

Indexed keywords

ANTALARMIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; UROCORTIN II; CORTICOTROPIN RELEASING FACTOR RECEPTOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; UROCORTIN;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DORSALATERAL PERIAQUEDUCTAL GRAY MATTER; DORSOMEDIAL PERIAQUEDUCTAL GRAY MATTER; ELECTROSTIMULATION; ELEVATED T-MAZE TEST; ESCAPE BEHAVIOR; MALE; NONHUMAN; PANIC; PERIAQUEDUCTAL GRAY MATTER; RAT; TRANQUILIZING ACTIVITY; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; ANXIETY; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; MICROINJECTION; PHYSIOLOGY;

ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; CORTICOTROPIN-RELEASING HORMONE; DISEASE MODELS, ANIMAL; MALE; MICROINJECTIONS; PANIC; PERIAQUEDUCTAL GRAY; PYRIMIDINES; PYRROLES; RATS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; UROCORTINS;

EID: 84922430809     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2014.07.026     Document Type: Article

References (54)

1. Amat J., Tamblyn J.P., Paul E.D., Bland S.T., Amat P., Foster A.C., Watkins L.R., Maier S.F. Microinjection of urocortin 2 into the dorsal raphe nucleus activates serotonergic neurons and increases extracellular serotonin in the basolateral amygdala. Neuroscience 2004, 129:509-519.
2. Arborelius L., Owens M.J., Plotsky P.M., Nemeroff C.B. The role of corticotropin-releasing factor in depression and anxiety disorders. J. Endocrinol. 1999, 160:1-12.
3. Bailey J.E., Papadopoulos A., Diaper A., Phillips S., Schmidt M., van der Ark P., Dourish C.T., Dawson G.R., Nutt D.J. Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317573 in the 7.5% CO(2) proof-of-concept experimental model of human anxiety. J. Psychopharmacol. (Oxf.) 2011, 25:1199-1206.
4. Bale T.L. Sensitivity to stress: dysregulation of CRF pathways and disease development. Horm. Behav. 2005, 48:1-10.
5. Bale T.L., Contarino A., Smith G.W., Chan R., Gold L.H., Sawchenko P.E., Koob G.F., Vale W.W., Lee K.F. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat. Genet. 2000, 24:410-414.
6. Binder E.B., Nemeroff C.B. The CRF system, stress, depression and anxiety-insights from human genetic studies. Mol. Psychiatry 2010, 15:574-588.
7. Blanchard D.C., Blanchard R.J., Griebel G. Defensive responses to predator threat in the rat and mouse. Curr. Protoc. Neurosci. 2005, Chapter 8, Unit 8.19.
8. Blanchard D.C., Griebel G., Blanchard R.J. The mouse defense test battery: pharmacological and behavioral assays for anxiety and panic. Eur. J. Pharmacol. 2003, 463:97-116.
9. Blanchard R.J., Taukulis H.K., Rodgers R.J., Magee L.K., Blanchard D.C. Yohimbine potentiates active defensive responses to threatening stimuli in Swiss-Webster mice. Pharmacol. Biochem. Behav. 1993, 44:673-681.
10. Borelli K.G., Albrechet-Souza L., Fedoce A.G., Fabri D.S., Resstel L.B., Brandao M.L. Conditioned fear is modulated by CRF mechanisms in the periaqueductal gray columns. Horm. Behav. 2013, 63:791-799.
11. Borelli K.G., Brandao M.L. Effects of ovine CRF injections into the dorsomedial, dorsolateral and lateral columns of the periaqueductal gray: a functional role for the dorsomedial column. Horm. Behav. 2008, 53:40-50.
12. Carrive P., Paxinos G. The supraoculomotor cap: a region revealed by NADPH diaphorase histochemistry. Neuroreport 1994, 5:2257-2260.
13. Carvalho-Netto E.F., Litvin Y., Nunes-de-Souza R.L., Blanchard D.C., Blanchard R.J. Effects of intra-PAG infusion of ovine CRF on defensive behaviors in Swiss-Webster mice. Behav. Brain Res. 2007, 176:222-229.
14. Casarotto P.C., de Bortoli V.C., Corrêa F.M., Resstel L.B., Zangrossi H. Panicolytic-like effect of BDNF in the rat dorsal periaqueductal grey matter: the role of 5-HT and GABA. Int. J. Neuropsychopharmacol. 2010, 13(5):573-582.
15. de Paula Soares V., Zangrossi H. Stimulation of 5-HT1A or 5-HT2A receptors in the ventrolateral periaqueductal gray causes anxiolytic-, but not panicolytic-like effect in rats. Behav. Brain Res. 2009, 197(1):178-185.
16. Del-Ben C.M., Graeff F.G. Panic disorder: is the PAG involved?. Neural Plas. 2009, 108-135.
17. Eckart K., Radulovic J., Radulovic M., Jahn O., Blank T., Stiedl O., Spiess J. Actions of CRF and its analogs. Curr. Med. Chem. 1999, 6:1035-1053.
18. Farrokhi C.B., Tovote P., Blanchard R.J., Blanchard D.C., Litvin Y., Spiess J. Cortagine: behavioral and autonomic function of the selective CRF receptor subtype 1 agonist. CNS Drug Rev. 2007, 13:423-443.
19. Graeff F.G. On serotonin and experimental anxiety. Psychopharmacology (Berl.) 2002, 163:467-476.
20. Graeff F.G., Zangrossi H. Animal models of anxiety disorders. Biological Psychiatry 2002, 879-893. John Wiley & Sons, London. H. D'haenen, J.A. den Boer, P. Willner (Eds.).
21. Griez E., Schruers K. Experimental pathophysiology of panic. J. Psychosom. Res. 1998, 45:493-503.
22. Henry B., Vale W., Markou A. The effect of lateral septum corticotropin-releasing factor receptor 2 activation on anxiety is modulated by stress. J. Neurosci. 2006, 26:9142-9152.
23. Hogg S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol. Biochem. Behav. 1996, 54:21-30.
24. Ishitobi Y., Nakayama S., Yamaguchi K., Kanehisa M., Higuma H., Maruyama Y., Ninomiya T., Okamoto S., Tanaka Y., Tsuru J., Hanada H., Isogawa K., Akiyoshi J. Association of CRHR1 and CRHR2 with major depressive disorder and panic disorder in a Japanese population. Am. J. Med. Genet. 2012, 159B:429-436.
25. Janssen D., Kozicz T. Is it really a matter of simple dualism? Corticotropin-releasing factor receptors in body and mental health. Front. Endocrinol. 2013, 4:28.
26. Jenck F., Moreau J.L., Martin J.R. Dorsal periaqueductal gray-induced aversion as a simulation of panic anxiety: elements of face and predictive validity. Psychiatry Res. 1995, 57:181-191.
27. Karteris E., Papadopoulou N., Grammatopoulos D.K., Hillhouse E.W. Expression and signalling characteristics of the corticotrophin-releasing hormone receptors during the implantation phase in the human endometrium. J. Mol. Endocrinol. 2004, 32:21-32.
28. Keck M.E., Kern N., Erhardt A., Unschuld P.G., Ising M., Salyakina D., Muller M.B., Knorr C.C., Lieb R., Hohoff C., Krakowitzky P., Maier W., Bandelow B., Fritze J., Deckert J., Holsboer F., Muller-Myhsok B., Binder E.B. Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder. Am. J. Med. Genet. 2008, 147B:1196-1204.
29. Kishimoto T., Radulovic J., Radulovic M., Lin C.R., Schrick C., Hooshmand F., Hermanson O., Rosenfeld M.G., Spiess J. Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat. Genet. 2000, 24:415-419.
30. Litvin Y., Pentkowski N.S., Blanchard D.C., Blanchard R.J. CRF type 1 receptors in the dorsal periaqueductal gray modulate anxiety-induced defensive behaviors. Horm. Behav. 2007, 52:244-251.
31. Lovick T.A., Parry D.M., Stezhka V.V., Lumb B.M. Serotonergic transmission in the periaqueductal gray matter in relation to aversive behaviour: morphological evidence for direct modulatory effects on identified output neurons. Neuroscience 2000, 95:763-772.
32. Marseillan R.F. A solid state sine-wave stimulator. Physiol. Behav. 1977, 19:339-340.
33. Martins A.P., Marras R.A., Guimaraes F.S. Anxiogenic effect of corticotropin-releasing hormone in the dorsal periaqueductal grey. Neuroreport 1997, 8:3601-3604.
34. McNaughton N., Corr P.J. A two-dimensional neuropsychology of defense: fear/anxiety and defensive distance. Neurosci. Biobehav. Rev. 2004, 28:285-305.
35. McNaughton N., Gray J.A. Anxiolytic action on the behavioural inhibition system implies multiple types of arousal contribute to anxiety. J. Affect. Disord. 2000, 61:161-176.
36. Merchenthaler I. Corticotropin releasing factor (CRF)-like immunoreactivity in the rat central nervous system. Extrahypothalamic distribution. Peptides 1984, 5(Suppl 1):53-69.
37. Miguel T.T., Nunes-de-Souza R.L. Anxiogenic and antinociceptive effects induced by corticotropin-releasing factor (CRF) injections into the periaqueductal gray are modulated by CRF1 receptor in mice. Horm. Behav. 2011, 60:292-300.
38. Moreira F.A., Gobira P.H., Viana T.G., Vicente M.A., Zangrossi H., Graeff F.G. Modeling panic disorder in rodents. Cell Tissue Res. 2013, 354(1):119-125.
39. Nashold B.S., Wilson W.P., Slaughter D.G. Sensations evoked by stimulation in the midbrain of man. J. Neurosurg. 1969, 30:14-24.
40. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 2007, Elsevier, Amsterdam. 6th ed.
41. Reul J.M., Holsboer F. On the role of corticotropin-releasing hormone receptors in anxiety and depression. Dialogues Clin. Neurosci. 2002, 4:31-46.
42. Risbrough V.B., Hauger R.L., Roberts A.L., Vale W.W., Geyer M.A. Corticotropin-releasing factor receptors CRF1 and CRF2 exert both additive and opposing influences on defensive startle behavior. J. Neurosci. 2004, 24(29):6545-6552.
43. Risbrough V.B., Stein M.B. Role of corticotropin releasing factor in anxiety disorders: a translational research perspective. Horm. Behav. 2006, 50:550-561.
44. Schenberg L.C. Towards a translational model of panic attack. Psychol. Neurosci. 2010, 3:9-37.
45. Sajdyk T.J., Schober D.A., Gehlert D.R., Shekhar A. Role of corticotropin-releasing factor and urocortin within the basolateral amygdala of rats in anxiety and panic responses. Brain Res. 1999, 100(1-2):207-215.
46. Smoller J.W., Yamaki L.H., Fagerness J.A., Biederman J., Racette S., Laird N.M., Kagan J., Snidman N., Faraone S.V., Hirshfeld-Becker D., Tsuang M.T., Slaugenhaupt S.A., Rosenbaum J.F., Sklar P.B. The corticotropin-releasing hormone gene and behavioral inhibition in children at risk for panic disorder. Biol. Psychiatry 2005, 57:1485-1492.
47. Swanson L.W., Sawchenko P.E., Rivier J., Vale W.W. Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology 1983, 36:165-186.
48. Teixeira R.C., Zangrossi H., Graeff F.G. Behavioral effects of acute and chronic imipramine in the elevated T-maze model of anxiety. Pharmacol. Biochem. Behav. 2000, 65:571-576.
49. Valdez G.R. Development of CRF1 receptor antagonists as antidepressants and anxiolytics: progress to date. CNS Drugs 2006, 20:887-896.
50. Valdez G.R., Zorrilla E.P., Rivier J., Vale W.W., Koob G.F. Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasing factor agonist. Brain Res. 2003, 980:206-212.
51. Vale W., Rivier C., Brown M.R., Spiess J., Koob G., Swanson L., Bilezikjian L., Bloom F., Rivier J. Chemical and biological characterization of corticotropin releasing factor. Recent Prog. Horm. Res. 1983, 39:245-270.
52. Vaughan J., Donaldson C., Bittencourt J., Perrin M.H., Lewis K., Sutton S., Chan R., Turnbull A.V., Lovejoy D., Rivier C., et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995, 378:287-292.
53. Zangrossi H., Graeff F.G. Serotonin in anxiety and panic: Contributions of the elevated T-maze. Neurosci. Biobehav. Rev. 2014, 10.1016/j.neubiorev.2014.03.007.
54. Zangrossi H., Graeff F.G. Behavioral validation of the elevated T-maze, a new animal model of anxiety. Brain Res. Bull. 1997, 44:1-5.